Arcturus Therapeutics Holdings (ARCT) Total Non-Current Liabilities (2021 - 2023)

Arcturus Therapeutics Holdings' Total Non-Current Liabilities history runs 3 years deep, the most recent figure standing at $150.4 million for Q4 2023.

• Quarterly Total Non-Current Liabilities fell 15.16% year-over-year to $150.4 million in Q4 2023, while the trailing twelve-month figure through Dec 2023 was $150.4 million (down 15.16% YoY) and the FY2023 annual result came in at $150.4 million, down 15.16% from the prior year.
• Total Non-Current Liabilities was $150.4 million for Q4 2023 at Arcturus Therapeutics Holdings, down from $176.6 million in the prior quarter.
• Across five years, Total Non-Current Liabilities topped out at $177.3 million in Q4 2022 and bottomed at $128.5 million in Q1 2021.
• A 3-year average of $153.0 million and a median of $144.3 million in 2022 frame the typical range for Total Non-Current Liabilities.
• Annual changes were most pronounced in 2022 — Total Non-Current Liabilities slipped 17.09% — and 2023, when it rose 22.41%.
• Arcturus Therapeutics Holdings' Total Non-Current Liabilities stood at $174.0 million in 2021, then climbed by 1.87% to $177.3 million in 2022, then retreated by 15.16% to $150.4 million in 2023.
• Business Quant data shows ARCT's Total Non-Current Liabilities at $150.4 million in Q4 2023, $176.6 million in Q3 2023, and $144.2 million in Q2 2023.